BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20451877)

  • 1. Alzheimer's disease neuroimaging initiative in Europe.
    Frisoni GB
    Alzheimers Dement; 2010 May; 6(3):280-5. PubMed ID: 20451877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).
    Buerger K; Frisoni G; Uspenskaya O; Ewers M; Zetterberg H; Geroldi C; Binetti G; Johannsen P; Rossini PM; Wahlund LO; Vellas B; Blennow K; Hampel H
    Exp Gerontol; 2009 Sep; 44(9):579-85. PubMed ID: 19539742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
    Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neurochemical early and differential diagnostics for Alzheimer's disease].
    Wiltfang J; Lewczuk P; Maler M; Bleich S; Smirnov A; Kornhuber J
    MMW Fortschr Med; 2004 Sep; 146(38):38-40. PubMed ID: 15532429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interest of CSF beta-amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer's disease].
    Smach MA; Charfeddine B; Lammouchi T; Dridi H; Ben Othman L; Bennamou S; Limem K
    Ann Biol Clin (Paris); 2008; 66(5):531-5. PubMed ID: 18957342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative.
    Ellis KA; Rowe CC; Villemagne VL; Martins RN; Masters CL; Salvado O; Szoeke C; Ames D;
    Alzheimers Dement; 2010 May; 6(3):291-6. PubMed ID: 20451879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
    Galasko D
    J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
    Stuerenburg HJ; Ganzer S; Müller-Thomsen T
    Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Rusinek H; Li J; Tsui W; Saint Louis LA; Clark CM; Tarshish C; Li Y; Lair L; Javier E; Rich K; Lesbre P; Mosconi L; Reisberg B; Sadowski M; DeBernadis JF; Kerkman DJ; Hampel H; Wahlund LO; Davies P
    Neurobiol Aging; 2006 Mar; 27(3):394-401. PubMed ID: 16125823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Japanese Alzheimer's Disease Neuroimaging Initiative: present status and future.
    Iwatsubo T
    Alzheimers Dement; 2010 May; 6(3):297-9. PubMed ID: 20451880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
    Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
    Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The progress of Alzheimer's disease research biomarkers--sensitivity and specificity].
    Shoji M
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1234-6. PubMed ID: 11464465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
    Andreasen N; Blennow K
    Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.